A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
terminated

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)

study id #: NCT00140894

condition: Adenomatous Polyposis Coli

status: terminated

purpose:

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

intervention:
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks

start date: March 1, 2003

estimated completion: Not Available

last updated: September 29, 2017

phase of development: Phase 4

size / enrollment: 62

study design:
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

primary outcomes:

  • Number and average size of rectal polyps
  • Safety and tolerability

secondary outcomes:

  • Number and average size of duodenal polyps
  • Proportions of patients with improved overall colon rating

inclusion criteria:
- Males or females at least 18 years of age with familial adenomatous polyposis.

exclusion criteria:

sponsor: Merck Sharp & Dohme Corp.

investigators: Medical Monitor, Merck Sharp & Dohme Corp.

investigators: Medical Monitor, Merck Sharp & Dohme Corp.

locations: Canada

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close